Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_assertion type Assertion NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_head.
- NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_assertion description "[Studies have shown that mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain are associated with response of lung cancer to gefitinib (Iressa, AstraZeneca Corp., Shanghai, China).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_provenance.
- NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_assertion evidence source_evidence_literature NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_provenance.
- NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_assertion SIO_000772 15958609 NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_provenance.
- NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_assertion wasDerivedFrom befree-2016 NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_provenance.
- NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_assertion wasGeneratedBy ECO_0000203 NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_provenance.